Last reviewed · How we verify

EI-1071 tablet, oral — Competitive Intelligence Brief

EI-1071 tablet, oral (EI-1071 tablet, oral) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

phase 2 Small molecule Live · refreshed every 30 min

Target snapshot

EI-1071 tablet, oral (EI-1071 tablet, oral) — Elixiron Immunotherapeutics (Hong Kong) Ltd..

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
EI-1071 tablet, oral TARGET EI-1071 tablet, oral Elixiron Immunotherapeutics (Hong Kong) Ltd. phase 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EI-1071 tablet, oral — Competitive Intelligence Brief. https://druglandscape.com/ci/ei-1071-tablet-oral. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: